To compare the pharmacodynamic effects of the highest approved doses of the sodium glucose co-transporter @ ( SGLT@ ) inhibitors canagliflozin and dapagliflozin on urinary glucose excretion ( UGE ) , renal threshold for glucose excretion ( RTG ) and postprandial plasma glucose ( PPG ) excursion in healthy participants in a randomized , double-blind , two-period crossover study .